PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...

Jazz Pharmaceuticals announced that the FDA has approved ZIIHERA® (zanidatamab-hrii) on an accelerated basis for the treatment ...

The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...

Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that ...

The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for ...

Among the heavily pretreated NSCLC EGFR wild-type patients, the combination therapy demonstrated an overall response rate of 21 percent, and a disease control rate of 76 percent. Moreover, tumor ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

In 33 heavily pretreated NSCLC EGFR wild-type (EGFRwt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of ...

Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024. See why I rate ...

This would prevent the patients receiving unnecessary treatment and provide them with alternative options that will give them the best chance of beating the disease ... shows therapy-resistant ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

NEW YORK – Ideaya Biosciences said on Monday that it plans to develop a KAT6/7 inhibitor, IDE251, as treatment for breast and lung cancer patients whose tumors harbor 8p11 amplifications.